One reason patients hesitate to join research is simple: they cannot picture what happens after they say yes.
They can imagine the big words. Screening. Consent. Study visits. Monitoring. Follow-up.
What they cannot always imagine is the lived reality. Who do you meet first? How long are the appointments? Are you constantly being tested? What happens if you feel unwell? Can you leave the study later if it no longer feels right?
If you have been looking for what to expect during a clinical trial, this guide is for that moment. Not the first spark of curiosity. The moment after that, when interest turns into a need for specifics.
First, expect a process, not a single appointment
Clinical trials do not usually begin with treatment on day one.
There is often a sequence:
- initial contact or pre-screening
- formal screening
- informed consent
- baseline assessments
- study visits and monitoring
- follow-up
The exact order varies by protocol, but the important thing is this: research participation is structured. Trials follow written protocols that define what happens, when it happens, and who is eligible.
That structure can feel unfamiliar, but it is also what makes the experience more predictable than many patients expect.
What happens at pre-screening
Pre-screening is often your first real interaction with the study team.
This may happen by phone, online, or in person. The goal is to see whether the study is worth exploring further. The team may ask about your condition, age, prior treatments, symptoms, and basic medical history.
This step is not a promise of enrollment. It is a filter.
That can feel disappointing if you are eager to move forward, but it is also respectful of your time. It is better to identify obvious mismatches early than to bring someone through a long process only to discover they were never eligible.
What happens at screening
If pre-screening looks promising, you may be scheduled for a screening visit.
Screening is where the site determines whether you meet the trial’s eligibility criteria. Depending on the study, that can include medical record review, lab work, imaging, physical exams, medication review, pregnancy testing, or other assessments. Each study has its own rules about who can take part.
Sometimes patients assume screening is just a formality. It usually is not.
The study may need to confirm details that were not obvious from the first conversation. You might meet some criteria and miss others. You may need outside records. You may need to wait for results.
This is normal. Screening is one of the most important gates in the process.
What informed consent really looks like
Patients often picture consent as a signature at the bottom of a packet.
That is the smallest part of it.
The real consent process is the conversation. The study team should explain:
- what the study is for
- what procedures are involved
- what the known risks are
- what the possible benefits are
- what alternatives exist
- what your rights are as a participant
FDA patient guidance states that informed consent is meant to help patients decide whether to join and that they should ask about anything they do not understand. FDA’s broader guidance also says the consent process continues throughout the study, not just at the moment the form is signed.
That is worth repeating. The process continues.
If new information comes up later, you should be told. If the protocol changes in a way that affects you, that should be explained.
What study visits may involve
Once you are enrolled, study visits begin according to the protocol.
Some visits are short and simple. Others are longer. Depending on the trial, visits may include:
- physical exams
- bloodwork
- questionnaires
- review of symptoms or side effects
- medication administration
- imaging
- device checks
- diaries or app-based reporting
This is one reason no two clinical trials feel exactly alike.
A study testing a drug may look very different from a behavioral study or an observational study. NIH and NCI materials explain that trials vary widely in purpose and procedures, which is why patients should ask for a practical walk-through of the schedule before enrolling.
Expect monitoring, not just appointments
A clinical trial is not only a series of calendar slots. It is also a monitoring process.
The research team may track lab values, symptoms, vital signs, treatment response, and side effects over time. Safety monitoring is part of the design, not an afterthought. NCI notes that patient safety in trials is supported through the informed consent process, protocol review, and ongoing monitoring.
For patients, that usually means two things.
First, you may be watched more closely than you would be in routine care, especially during certain parts of the study.
Second, you need to report changes honestly and promptly, even when they seem small.
What if you have side effects or concerns
This is where patients often want the most reassurance.
You should know:
- who to contact during office hours
- who to contact after hours
- what symptoms need urgent attention
- whether to call the site, your doctor, or emergency services in a serious situation
Do not wait until you are uncomfortable to ask this.
A good site will explain communication clearly. They will tell you what to do if something changes at home. You should not have to guess.
Will you definitely receive the treatment you hope for?
Not always.
Some trials compare a new treatment with standard treatment, another regimen, or, in some cases, a placebo, depending on the study design. Not all trials use placebos, and not all studies are designed the same way.
That is why the consent conversation matters so much. Patients should understand what treatment pathway is possible in that specific trial, rather than assuming all trials work the same way.
What follow-up means
Many patients think participation ends the moment the active treatment part is over. Sometimes it does not.
Some studies include follow-up visits, safety calls, repeat labs, or later assessments to understand outcomes over time. That is part of how researchers learn whether a treatment remained safe, how long effects lasted, or whether additional issues appeared later.
Follow-up is still part of participation. Ask how long it lasts and what it involves.
Can you leave a clinical trial after joining?
Yes. You can leave the clinical trial at any time. Participation is voluntary. But stopping doesn’t mean you simply disappear from the schedule. For your own safety and responsible care, the study team may recommend certain follow-up steps. Understand what withdrawal looks like before you enroll, not after you are already frustrated.
What patients often say they did not expect
Here is the part people usually leave out.
Patients often do not expect how administrative some parts of research can feel. Forms. Scheduling. Record requests. Waiting for eligibility confirmation. Repeating details more than once.
They also do not expect how helpful a steady study coordinator can be.
A good coordinator does more than move paper. They translate the process. They help patients understand where they are in the sequence and what happens next. That does not make research effortless, but it does make it feel navigable.
How to prepare yourself before the first visit
A few simple steps can make the process easier:
- bring a list of medications
- bring questions in writing
- ask whether records are needed in advance
- bring a support person if you want one
- ask for the visit timeline
- clarify transportation and parking details
- request plain-language explanations when needed
None of that is overkill. It is preparation.
Conclusion
When patients ask what to expect during a clinical trial, what they are usually asking is whether the process will feel confusing, risky, or overwhelming.
The honest answer is that it can feel unfamiliar. But it should not feel hidden.
You should know what screening is for. You should know what consent means. You should know what visits involve, how safety is monitored, and what happens if you want to stop.
The more clearly a research site explains those steps, the easier it becomes to make a thoughtful decision about whether participation is right for you.
FAQ
What happens first in a clinical trial?
Usually there is an initial contact or pre-screening step, followed by screening, informed consent, and then study-specific baseline or treatment visits if you qualify.
Are clinical trials closely monitored?
Yes. Patient safety is supported through protocol oversight, the informed consent process, and ongoing monitoring during the study.
Can I stop participating after a clinical trial starts?
Yes. Participation is voluntary, though the team may recommend certain follow-up steps to support safety if you withdraw.
Trial participation is voluntary. You can leave at any time. If you decide to go, talk to the study team first. They will help you exit safely and ensure any necessary final checks are completed.
Take the Next Step: Join the Healix by Denali Registry
The Healix by Denali Health Patient Registry is a simple, low-commitment way to stay connected to future research that matches your specific health profile.
By joining the registry, you will:
- Stay Informed: Receive updates directly from our clinical research team about new studies that match your conditions.
- Keep Your Options Open: Maintain a path to accessing cutting-edge investigational therapies down the line.
- Contribute to Medicine: Help Denali Health better understand the patient community, which is essential for accelerating new treatments.
Join the Healix Registry today and keep your health journey moving forward.
Author Box: Denali Content Team
Disclaimer: This article was written for educational purposes and reviewed for accuracy by experienced clinical research professionals. It is not medical advice.